| Effect of targeted therapy combined with immune checkpoint inhibitors on cardiac troponin T in patients with hepatocellular carcinoma |
| Received:April 25, 2022 Revised:October 13, 2022 Click here to download the full text |
| Citation of this paper:GUO Xin-kun,CHEN Xiao-chun,ZHENG Su-su,WU Yan-fang,XIE Xiao-ying,ZHANG Bo-heng.Effect of targeted therapy combined with immune checkpoint inhibitors on cardiac troponin T in patients with hepatocellular carcinoma[J].Chinese Journal of Clinical Medicine,2023,30(2):272-278 |
| Hits: 777 |
| Download times: 375 |
| Author Name | Affiliation | E-mail | | GUO Xin-kun | Department of Hepatic Oncology, Zhongshan Hospital, Fudan University(Xiamen Branch), Xiamen 361015, Fujian, China
Xiamen Clinical Medical Research Center for Comprehensive Treatment of Malignant Tumor, Xiamen 361015, Fujian, China | | | CHEN Xiao-chun | Department of Hepatic Oncology, Zhongshan Hospital, Fudan University(Xiamen Branch), Xiamen 361015, Fujian, China
Xiamen Clinical Medical Research Center for Comprehensive Treatment of Malignant Tumor, Xiamen 361015, Fujian, China | | | ZHENG Su-su | Department of Hepatic Oncology, Zhongshan Hospital, Fudan University(Xiamen Branch), Xiamen 361015, Fujian, China
Xiamen Clinical Medical Research Center for Comprehensive Treatment of Malignant Tumor, Xiamen 361015, Fujian, China | | | WU Yan-fang | Department of Hepatic Oncology, Zhongshan Hospital, Fudan University(Xiamen Branch), Xiamen 361015, Fujian, China
Xiamen Clinical Medical Research Center for Comprehensive Treatment of Malignant Tumor, Xiamen 361015, Fujian, China | | | XIE Xiao-ying | Department of Hepatic Oncology, Zhongshan Hospital, Fudan University(Xiamen Branch), Xiamen 361015, Fujian, China
Xiamen Clinical Medical Research Center for Comprehensive Treatment of Malignant Tumor, Xiamen 361015, Fujian, China
Department of Hepatic Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | ZHANG Bo-heng | Department of Hepatic Oncology, Zhongshan Hospital, Fudan University(Xiamen Branch), Xiamen 361015, Fujian, China
Xiamen Clinical Medical Research Center for Comprehensive Treatment of Malignant Tumor, Xiamen 361015, Fujian, China
Department of Hepatic Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | zhang.boheng@zs-hospital.sh.cn |
|
| Abstract:Objective To explore the incidence and clinical characteristics of cardiac troponin T (cTnT) elevation in patients with hepatocellular carcinoma who received targeted combined with immune checkpoint inhibitors (ICIs) therapy. Methods From January 2017 to December 2021, 125 patients with hepatocellular carcinoma treated with targeted combined with ICIs therapy in Zhongshan Hospital, Fudan University (Xiamen Branch) were collected. Patients were divided into cTnT normal group (cTnT＜0.03 ng/mL, n=114) and cTnT elevated group (cTnT≥0.03 ng/mL, n=11) according to the changes in cTnT levels during treatment. The baseline characteristics between the two groups, the clinical changes before and after cTnT elevation in cTnT elevated groups were analyzed. Results cTnT elevation occurred in 11 patients (8.8%), including 1 myocarditis (0.8%). Elder age, history of cardiovascular disease, history of diabetes might be risk factors for cTnT elevation. After cTnT elevation, decreased left ventricular ejection fraction (P=0.020), decreased left ventricular end diastolic diameter (P=0.013) and increased interleukin-2 receptor (P=0.038) were found. Conclusions Targeted therapy combined with ICIs could lead to cTnT elevation in some patients with hepatocellular carcinoma. Monitoring cTnT changes is helpful for early detection of myocardial injury and has important implications for the prevention of medication related cardiac adverse events. |
| keywords:hepatocellular carcinoma targeted therapy immune checkpoint inhibitors cardiac troponin T |
| HTML View Full Text View/Add Comment Download reader |
|
|
|